Gavreto, Arcalyst Available Through AllianceRx Walgreens Prime
Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.
Specialty and home delivery pharmacy AllianceRX Walgreens Prime is now carrying Arcalyst (rilonacept)developed by Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals and Gavreto (pralsetinib) developed by Blueprint Medicines.
The FDA approved Arcalyst in March 2020. It is the only FDA-approved product for the treatment of recurrent pericarditis and reduction in risk of recurrence in patients 12 years of age and older, AllianceRx Walgreens Prime said in a news release. Pericarditis is a painful and debilitating autoinflammatory cardiovascular disease associated with swelling of the saclike membrane surrounding the heart.
Arcalyst’s net revenue in the second quarter of 2021 — the first quarter it was available — reached $7.7 million.
Arcalyst is also approved to treat cryopyrin-associated periodic syndromes (CAPS), a group of rare hereditary autoinflammatory disorders, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, and for the maintenance of remission of deficiency of interleukin-1 receptor antagonist (DIRA), an autoinflammatory disease affecting fewer than 50 people worldwide.
Gavreto, a once-daily oral medication, is used to treat certain cancers caused by abnormal RET-positive genes in metastatic nonsmall cell lung cancer or advanced thyroid cancer that may have spread.
Approved by the FDA September 2020, Gavreto had $1.8 million in net product revenue during the first quarter of 2021, according to Blueprint.
Tracey James
“Patients living with these rare autoinflammatory disorders and cancers deserve access to the best treatment options available to help them manage these conditions,” Tracey James, senior vice president of Pharmacy Services at AllianceRx Walgreens Prime, said in a statement.
“Our specialty pharmacists engage and counsel patients about prescribed therapy and help improve adherence and persistence. Manufacturers partner with us because of our continual commitment to providing patients with individualized support and clinical expertise required to improve patient outcomes,” James added.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
